{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:21:28Z","timestamp":1793701288317,"version":"4.5.1"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"30","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2019,10,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and replace chemoimmunotherapy for many patients. However, individually, they rarely lead to eradication of measurable residual disease (MRD) and usually are taken indefinitely or until progression. We present the CLARITY trial that combined ibrutinib with venetoclax to eradicate detectable CLL with the intention of stopping therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>CLARITY is a phase II trial that combined ibrutinib with venetoclax in patients with relapsed or refractory CLL. The primary end point was eradication of MRD after 12 months of combined therapy. Key secondary end points were response by International Workshop on CLL criteria, safety, and progression-free and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>In 53 patients after 12 months of ibrutinib plus venetoclax, MRD negativity (fewer than one CLL cell in 10,000 leukocytes) was achieved in the blood of 28 (53%) and the marrow of 19 (36%). Forty-seven patients (89%) responded, and 27 (51%) achieved a complete remission. After a median follow-up of 21.1 months, one patient progressed, and all patients were alive. A single case of biochemical tumor lysis syndrome was observed. Other adverse effects were mild and\/or manageable and most commonly were neutropenia or GI events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The combination of ibrutinib plus venetoclax was well tolerated in patients with relapsed or refractory CLL. There was a high rate of MRD eradication that led to the cessation of therapy in some patients. The progression-free and overall survival rates are encouraging for relapsed and refractory CLL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.19.00894","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T15:55:38Z","timestamp":1562860538000},"page":"2722-2729","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":255,"title":["Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study"],"prefix":"10.1200","volume":"37","author":[{"given":"Peter","family":"Hillmen","sequence":"first","affiliation":[{"name":"Leeds Institute of Medical Research at St James\u2019s, University of Leeds, Leeds, United Kingdom"},{"name":"St James\u2019s Institute of Oncology, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy C.","family":"Rawstron","sequence":"additional","affiliation":[{"name":"St James\u2019s Institute of Oncology, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Brock","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Mu\u00f1oz-Vicente","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca J.","family":"Yates","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bishop","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Boucher","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fegan","sequence":"additional","affiliation":[{"name":"University Hospital of Wales, Cardiff, United Kingdom"},{"name":"Vale University Health Board, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"McCaig","sequence":"additional","affiliation":[{"name":"Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pettitt","sequence":"additional","affiliation":[{"name":"University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piers E.M.","family":"Patten","sequence":"additional","affiliation":[{"name":"Kings College Hospital NHS Foundation Trust, London, United Kingdom"},{"name":"King's College London, School of Cancer & Pharmaceutical Sciences, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Devereux","sequence":"additional","affiliation":[{"name":"Kings College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[{"name":"Christie Hospital NHS Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Fox","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Forconi","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"},{"name":"Cancer Sciences Unit, Cancer Research UK and NIHR Experimental Cancer Medicine Centres, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Munir","sequence":"additional","affiliation":[{"name":"St James\u2019s Institute of Oncology, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-6-200609190-00007"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390989"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0781"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2187-9"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.122"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"B14","doi-asserted-by":"crossref","first-page":"LBA-4","DOI":"10.1182\/blood-2018-120779","volume":"132","author":"Shanafelt TD","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810044"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-688796"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0955"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.07.098"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30012-8"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6840"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.313"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.721"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714162"}],"updated-by":[{"DOI":"10.1200\/jco.20.00411","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T00:00:00Z","timestamp":1589068800000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.19.00894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T04:45:27Z","timestamp":1653799527000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.00894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,20]]},"references-count":26,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2019,10,20]]}},"alternative-id":["10.1200\/JCO.19.00894"],"URL":"https:\/\/doi.org\/10.1200\/jco.19.00894","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,20]]},"assertion":[{"value":"2019-05-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}